CDC-RFA-CE-23-0005: Essentials for Childhood (EfC): Preventing Adverse Childhood Experiences through Data to Action
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCIPC notices from 2023.
Centers for Disease Control - NCIPC offered grants of up to $485,000 (at least $400,000) to any type of organization. It expected to make about 12 awards worth $29.1 million in total. Applications closed on June 12, 2023.
From the official notice on Grants.gov, last changed April 12, 2023. Checked November 7, 2026.
- Award ceiling$485,000
- Award floor$400,000
- Total funding$29.1 million
- Expected awards12
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 12, 2023 |
|---|---|
| Deadline | June 12, 2023 |
| Archived by Grants.gov | July 12, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
All applicants may apply for the optional enhanced activities. Applicants applying for the enhanced activities will be required to do one or more additional activities as described in the Approach, Evaluation and Performance Measurement, and Organizational Capacity sections of this NOFO.Applicants applying for the optional enhanced activities must clearly state their intent to apply for these activities in the project abstract. Funding for these activities will not be considered if it is not clearly stated in the project abstract.
Is this a realistic fit?
- Past Injury Prevention and Control Research and State and Community Based Programs awards averaged $2.2 million; this notice allows up to $485,000 per award.
- Most of the program's money (76% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
Essentials for Childhood (EfC): Preventing Adversity through Data to Action, a cooperative agreement designed to support states in the prevention of adverse childhood experiences (ACEs) and promotion of positive childhood experiences (PCEs). ACEs are preventable, potentially traumatic events that occur in childhood (0-17 years) such as experiencing or witnessing violence, experiencing neglect; witnessing violence in the home. Also included are aspects of the child’s environment that can undermine their sense of safety, stability, and bonding such as growing up in a household with substance use problems, mental health problems, or instability due to parental separation or incarceration of a parent, sibling or other member of the household. ACEs can have significant consequences, including associations with poor health outcomes (e.g., asthma, cancer, heart disease), health risk behaviors (e.g., current smoking and heavy drinking), mental health challenges (depression, anxiety), and socioeconomic challenges (e.g., unemployment and no health insurance). The three primary goals of this NOFO are to 1) enhance a state-level surveillance infrastructure that ensures the capacity to collect, analyze, and use ACE and PCE data to inform ACE prevention strategies and approaches; 2) support the implementation of data-driven, comprehensive, evidence-based ACE primary prevention strategies and approaches, particularly with a focus on health equity; and 3) conduct data to action activities on an ongoing basis to inform changes or adaptations to existing strategies or selection and implementation of additional strategies. Health equity is the attainment of the highest level of health for all people. Achieving health equity requires valuing everyone equally with focused and ongoing societal efforts to address avoidable inequalities, historical and contemporary injustices, and the elimination of health and healthcare disparities. Health inequities are health differences or disparities that are systematic, unfair, and avoidable. Social determinants of health (SDOH) are the conditions in which people are born, grow, live, learn, work, and age. The goal is for everyone to attain equitable access to life circumstances such as education, occupation, and income to achieve optimal health, well-being, and safety.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before
From fiscal 2021 to 2025, Injury Prevention and Control Research and State and Community Based Programs (93.136) awarded $2.2 billion across 986 grant awards, an average of $2.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Florida Department of Health | Florida | 12 | $81.1 million |
| California Department of Public Health | California | 11 | $55.4 million |
| Ohio Department of Health | Ohio | 9 | $42.0 million |
| North Carolina Department of Health & Human Services | North Carolina | 12 | $42.0 million |
| Michigan Department of Health and Human Services | Michigan | 10 | $37.9 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CE-23-0005 still open?
No. It closed on June 12, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Essentials for Childhood (EfC): Preventing Adverse Childhood Experiences through Data to Action?
Centers for Disease Control - NCIPC accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Essentials for Childhood (EfC): Preventing Adverse Childhood Experiences through Data to Action?
Closed June 12, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $485,000 each. About $29.1 million in total across about 12 awards.
Who has won Injury Prevention and Control Research and State and Community Based Programs grants before?
The largest recipients over five fiscal years were Florida Department of Health, California Department of Public Health, Ohio Department of Health. The program made 986 awards worth $2.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)